表紙
市場調查報告書
商品編碼
1043802

商檢市場:按產品類型、按技術、按分銷渠道:全球機會分析和行業預測(2021-2030)

Over The Counter Test Market by Product Type, Technology, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021--2030

出版日期: | 出版商: Allied Market Research | 英文 353 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2020年全球商檢市場規模達到134.985億美元。

預計 2021 年至 2030 年間,該市場將以 11.7% 的複合年增長率增長,到 2030 年達到 399.379 億美元。

全球商業檢測市場的增長是糖尿病、心血管疾病、呼吸道感染、HIV、腎臟/肝臟疾病、製藥/生物技術行業等慢性和傳染病患病率的增加。主要因素是政府對疾病發展的努力,增加商業檢驗產品的批准數量,開發先進的商業檢驗產品,以及增加早期診斷測試的引入。

本報告調查全球商業檢驗市場,按產品類型、技術、分銷渠道、地區和進入市場的公司概況提供市場概況、趨勢。

目錄

第1章介紹

第2章執行摘要

第3章市場情況

  • 市場定義和範圍
  • 主要調查結果
    • 主要投資領域
    • 主要成功策略
  • 波特五力分析
  • 2020 年主要進入者的定位
  • 市場動態
    • 促進因素
      • 慢性病和傳染病的患病率增加
      • 商檢產品獲批數量增加
      • 商業檢驗產品開發的技術進步
      • 疾病早期診斷需求快速增長
    • 抑製器
      • 診斷設備成本高
      • 缺乏技術意識
    • 市場機會
      • 全球醫療保健費用不斷增加
      • 主要進入者開發先進的驗房設備
    • 影響分析
  • 分析 COVID-19 對商檢市場的影響

第 4 章商業檢驗市場:按產品類型

  • 概覽
    • 市場規模和預測
    • 市場規模和預測
  • 血糖監測測試
    • 主要市場趨勢、增長因素和機遇
    • 血糖監測測試:按類型
      • 市場規模和預測
      • 市場交易量及預測
      • 血糖儀
      • 檢查條
      • 柳葉刀
    • 市場規模和預測:按地區
    • 市場容量和預測:按地區
    • 市場分析:按國家/地區
  • 妊娠試驗、不孕試驗
    • 主要市場趨勢、增長因素和機遇
    • 妊娠試驗、不孕試驗:按類型
      • 市場規模和預測
      • 市場交易量及預測
      • 驗孕
      • 產檢
    • 市場規模和預測:按地區
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區
  • 凝血監測試驗
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場容量和預測:按地區
    • 市場分析:按國家/地區
  • 尿液分析
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場容量和預測:按地區
    • 市場分析:按國家/地區
  • 膽固醇測試
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場容量和預測:按地區
    • 市場分析:按國家/地區
  • 其他檢查
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場容量和預測:按地區
    • 市場分析:按國家/地區

第 5 章商業檢驗市場:按技術

  • 概覽
    • 市場規模和預測
  • 側向流動分析
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區
  • 免疫分析
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區
  • 油尺
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區

第6章商檢市場:按分銷渠道

  • 概覽
    • 市場規模和預測
  • 院內藥房
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區
  • 零售藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區
  • 網上藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測:按地區
    • 市場分析:按國家/地區

第七章商檢市場:按地區劃分

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要市場趨勢、增長因素和機遇
    • 北美商業檢驗市場:按產品類型
    • 北美商檢市場:按技術分類
    • 北美商檢市場:按分銷渠道
    • 市場規模和預測:按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要市場趨勢、增長因素和機遇
    • 歐洲商業檢驗市場:按產品類型
    • 歐洲商業檢驗市場:按技術分類
    • 歐洲商業檢驗市場:按分銷渠道
    • 市場規模和預測:按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他
  • 亞太地區
    • 主要市場趨勢、增長因素和機遇
    • 亞太商業檢驗市場:按產品類型
    • 亞太商檢市場:按技術分類
    • 亞太商檢市場:按分銷渠道
    • 市場規模和預測:按國家/地區分類
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他
  • 拉丁美洲、中東、非洲
    • 主要市場趨勢、增長因素和機遇
    • 拉丁美洲、中東、非洲商業檢驗市場:按產品類型
    • 拉丁美洲、中東、非洲商業檢驗市場:按技術分類
    • 拉丁美洲、中東、非洲商業檢驗市場:按分銷渠道
    • 市場規模和預測:按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其他

第 8 章公司簡介

  • Abbott Laboratories
  • Abingdon Health PLC
  • AccuBioTech Co., Ltd
  • Acon Laboratories, INC.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Clip Health
  • Dario Health Corp.
  • Ellume Health Ltd.
  • Eurofins Scientific Group
  • F. Hoffmann-La Roche AG(Roche Diagnostics)
  • Lia Diagnostics Inc.
  • LifeScan IP Holdings, LLC
  • Lucira Health, Inc.
  • Now Diagnostics Inc.
  • Orasure Technologies Inc.
  • PHC Holdings Corporation
  • Quidel Corporation
  • SD Biosensor, Inc.
  • Sinocare Inc.
目錄
Product Code: A10465

The global over-the-counter test market was valued at $13,498.50 million in 2020, and is projected to reach $39,937.90 million by 2030, registering a CAGR of 11.7% from 2021 to 2030.

Over-the-counter (OTC) medical testing products are the products offered for sale directly to the consumer, without the need of prescription. There are wide range of over-the-counter testing products which got its Food and Drug Administrative approval for use by lay user. The consumers are able to understand how to use the device based on the labeling and instruction provided on the product, without any help from healthcare provider. Immunoassay, dipstick, and lateral flow assay, play a vital role in the manufacturing of over-the-counter testing products.

The growth of the global over-the-counter test market is majorly driven by alarming increase in the prevalence of chronic and infectious diseases, such as diabetics, cardiovascular disease, respiratory infection, HIV, kidney & liver disease; rise in government initiative for development of pharmaceutical and biotechnology industry; increase in number of approval for over-the-counter test product; development of advanced over-the-counter test product; and rise in adoption of early diagnosis testing. According to the World Health Organization (WHO) in 2021, various types of chronic diseases, such as cardiovascular diseases, cancer, respiratory diseases, and diabetes, are responsible for approximately 17.9 million, 9.3 million, 4.1 million, and 1.5 million deaths, respectively. Thus, the increase in prevalence of cardiovascular diseases, diabetes, and respiratory diseases surge the demand for cholesterol test, glucose monitoring test, and coagulation monitoring test. Moreover, in December 2020, the U.S. Food and drug administrative (FDA) announced the emergency authorization of Ellume COVID-19 Home test, for the over-the-counter use. It is a rapid antigen test, used for the detection of COVID-19 infection. Furthermore, in 2020, Scanwell, announced the partnership with Lemonaid Health to launch of smartphone-enable at-home test kits for the detection of urinary tract infection. It is the FDA approved urine testing kits available over-the-counter. Thus, advancements in technology for advanced over-the-counter test products in emerging nations and urinary tract infection are expected to propel the growth of the market.

The increase in government support for management of chronic disease and surge in demand for accurate and quick testing are the major factors that drive the global over-the-counter test market. For instance, in October 2021, the Australian Government announced the National Diabetes Services Scheme (NDSS), which provide products and services to help people in the management of diabetes. This scheme offers diabetic related products such as blood glucose test strips, and continuous glucose monitoring products. Moreover, in August 2021, Smart Meter, one of the leader in cellular connected remote patient monitoring device services, announced the availability of glucose monitor for the management of gestational diabetes. Thus, increase in incidence of diabetics significantly contributes toward the market growth. Rise in demand for early diagnosis of disease for effective treatment acts a key driving force for the expansion of the global market.

However, high cost associated with over-the-counter test products for detecting and monitoring of chronic and infectious disease is anticipated to hinder the market growth. People, now-a-day are aware of health, which in turn is compelling them to maintain their health condition and increase the demand for over-the-counter test product. This has further encouraged many key players to enter emerging markets, thus offering a lucrative growth opportunity in the over-the-counter test market.

The over-the-counter test market is segmented into product type, technology, distribution channel, and region. By product type, the market is categorized into glucose monitoring test, pregnancy & fertility test, infectious disease test, coagulation monitoring test, urinalysis test, cholesterol test, drugs-of-abuse test, and other test. By technology, it is fragmented into lateral flow assays, immunoassays, and dipsticks. As per end user, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global over-the-counter test market are Abbott Laboratories, Abingdon Health PLC, AccuBioTech Co., Ltd., Acon Laboratories Inc., B. Braun Melsungen AG, Becton Dickinson and Company, Clip Health, Dario Health Corp, Ellume Health Ltd, Eurofins Scientific Group, F. Hoffmann-La Roche AG, Lia Diagnostics Inc., Lifescan IP Holdings, LLC, Lucira Health, Inc., Now Diagnostics Inc., Orasure Technologies Inc., PHC Holdings Corporation, Quidel Corporation, SD Biosensor Inc., and Sinocare Inc..

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of the global over the counter test market size along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis on region assists to understand the regional market and facilitate the strategic business planning and determine prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global over the counter test market.

KEY MARKET SEGMENTS

By Product Type

  • Glucose Monitoring Test
  • Blood Glucose Meters
  • Testing Strips
  • Lancets
  • Pregnancy & Fertility Test
  • Pregnancy Test
  • Fertility Test
  • Coagulation Monitoring Test
  • Urinalysis Test
  • Other Test

By Technology

  • Lateral Flow Assays
  • Immunoassays
  • Dipsticks

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online pharmacy

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Abbott Laboratories
  • Abingdon Health PLC
  • AccuBioTech Co., Ltd.
  • Acon Laboratories Inc.
  • B. Braun Melsungen AG
  • Becton Dickinson and Company
  • Clip Health
  • Dario Health Corp
  • Ellume Health Ltd
  • Eurofins Scientific Group
  • F. Hoffmann-La Roche AG
  • Lia Diagnostics Inc
  • Lifescan IP Holdings, LLC
  • Lucira Health, Inc
  • Now Diagnostics Inc
  • Orasure Technologies Inc
  • PHC Holdings Corporation
  • Quidel Corporation
  • SD Biosensor Inc.
  • Sinocare Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Increase in prevalence of chronic and infectious disease
      • 3.5.1.2.Increase in number of approval for the over-the-counter tests product
      • 3.5.1.3.Advancement in technology to develop over-the-counter tests product
      • 3.5.1.4.Surge in demand for early diagnosis of disease
    • 3.5.2.Restraints
      • 3.5.2.1.High cost of diagnostic instruments
      • 3.5.2.2.Lack of awareness about technology among individual
    • 3.5.3.Opportunities
      • 3.5.3.1.Increase in healthcare expenditure worldwide
      • 3.5.3.2.Development of advanced at-home testing devices by key players
    • 3.5.4.Impact analysis
  • 3.6.Impact analysis of COVID-19 on the over-the-counter tests market

CHAPTER 4:OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE

  • 4.1.overview
    • 4.1.1.Market size and forecast
    • 4.1.2.Market Volume and forecast
  • 4.2.Glucose Monitoring Tests
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Glucose Monitoring Tests, by Type
      • 4.2.2.1.Market size and forecast
      • 4.2.2.2.Market volume and forecast
      • 4.2.2.3.Blood Glucose meters
      • 4.2.2.3.1.Market size and forecast
      • 4.2.2.4.Testing strips
      • 4.2.2.4.1.Market size and forecast
      • 4.2.2.5.Lancets
      • 4.2.2.5.1.Market size and forecast
    • 4.2.3.Market size and forecast, by region
    • 4.2.4.Market volume and forecast, by region
    • 4.2.5.Market analysis, by country
  • 4.3.Pregnancy & Fertility Tests
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Pregnancy and Fertility Tests, by Type
      • 4.3.2.1.Market size and forecast
      • 4.3.2.2.Market volume and forecast
      • 4.3.2.3.Pregnancy Test
      • 4.3.2.3.1.Market size and forecast
      • 4.3.2.4.Fertility Test
      • 4.3.2.4.1.Market size and forecast
    • 4.3.3.Market size and forecast, by region
    • 4.3.4.Market volume and forecast, by region
    • 4.3.5.Market analysis, by country
  • 4.4.Coagulation Monitoring Tests
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market volume and forecast, by region
    • 4.4.4.Market analysis, by country
  • 4.5.Urinalysis Tests
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market volume and forecast, by region
    • 4.5.4.Market analysis, by country
  • 4.6.Cholesterol Tests
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast, by region
    • 4.6.3.Market volume and forecast, by region
    • 4.6.4.Market analysis, by country
  • 4.7.Other Tests
    • 4.7.1.Key market trends, growth factors, and opportunities
    • 4.7.2.Market size and forecast, by region
    • 4.7.3.Market volume and forecast, by region
    • 4.7.4.Market analysis, by country

CHAPTER 5:OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY

  • 5.1.overview
    • 5.1.1.Market size and forecast
  • 5.2.Lateral Flow Assays
    • 5.2.1.Key market trends, growth factors, and opportunities
    • 5.2.2.Market size and forecast, by region
    • 5.2.3.Market analysis, by country
  • 5.3.Immunoassays
    • 5.3.1.Key market trends, growth factors, and opportunities
    • 5.3.2.Market size and forecast, by region
    • 5.3.3.Market analysis, by country
  • 5.4.Dipsticks
    • 5.4.1.Key market trends, growth factors, and opportunities
    • 5.4.2.Market size and forecast, by region
    • 5.4.3.Market analysis, by country

CHAPTER 6:OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1.overview
    • 6.1.1.Market size and forecast
  • 6.2.Hospital Pharmacies
    • 6.2.1.Key market trends, growth factors, and opportunities
    • 6.2.2.Market size and forecast, by region
    • 6.2.3.Market analysis, by country
  • 6.3.Retail Pharmacies
    • 6.3.1.Key market trends, growth factors, and opportunities
    • 6.3.2.Market size and forecast, by region
    • 6.3.3.Market analysis, by country
  • 6.4.Online Pharmacies
    • 6.4.1.Key market trends, growth factors, and opportunities
    • 6.4.2.Market size and forecast, by region
    • 6.4.3.Market analysis, by country

CHAPTER 7:OVER-THE-COUNTER TESTS MARKET, BY REGION

  • 7.1.overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.North America over-the-counter tests market, by product type
    • 7.2.3.North America over-the-counter tests market, by technology
    • 7.2.4.North America over-the-counter tests market, by distribution channel
    • 7.2.5.Market size and forecast, by country
      • 7.2.5.1.U.S.
      • 7.2.5.1.1.U.S. over-the-counter tests market, by product type
      • 7.2.5.1.2.U.S. over-the-counter tests market, by technology
      • 7.2.5.1.3.U.S. over-the-counter tests market, by distribution channel
      • 7.2.5.2.Canada
      • 7.2.5.2.1.Canada over-the-counter tests market, by product type
      • 7.2.5.2.2.Canada over-the-counter tests market, by technology
      • 7.2.5.2.3.Canada over-the-counter tests market, by distribution channel
      • 7.2.5.3.Mexico
      • 7.2.5.3.1.Mexico over-the-counter tests market, by product type
      • 7.2.5.3.2.Mexico over-the-counter tests market, by technology
      • 7.2.5.3.3.Mexico over-the-counter tests market, by distribution channel
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Europe over-the-counter tests market, by product type
    • 7.3.3.Europe over-the-counter tests market, by technology
    • 7.3.4.Europe over-the-counter tests market, by distribution channel
    • 7.3.5.Market size and forecast, by country
      • 7.3.5.1.Germany
      • 7.3.5.1.1.Germany over-the-counter tests market, by product type
      • 7.3.5.1.2.Germany over-the-counter tests market, by technology
      • 7.3.5.1.3.Germany over-the-counter tests market, by distribution channel
      • 7.3.5.2.France
      • 7.3.5.2.1.France over-the-counter tests market, by product type
      • 7.3.5.2.2.France over-the-counter tests market, by technology
      • 7.3.5.2.3.France over-the-counter tests market, by distribution channel
      • 7.3.5.3.UK
      • 7.3.5.3.1.UK over-the-counter tests market, by product type
      • 7.3.5.3.2.UK over-the-counter tests market, by technology
      • 7.3.5.3.3.UK over-the-counter tests market, by distribution channel
      • 7.3.5.4.Italy
      • 7.3.5.4.1.Italy over-the-counter tests market, by product type
      • 7.3.5.4.2.Italy over-the-counter tests market, by technology
      • 7.3.5.4.3.Italy over-the-counter tests market, by distribution channel
      • 7.3.5.5.Spain
      • 7.3.5.5.1.Spain over-the-counter tests market, by product type
      • 7.3.5.5.2.Spain over-the-counter tests market, by technology
      • 7.3.5.5.3.Spain over-the-counter tests market, by distribution channel
      • 7.3.5.6.Rest of Europe
      • 7.3.5.6.1.Rest of Europe over-the-counter tests market, by product type
      • 7.3.5.6.2.Rest of Europe over-the-counter tests market, by technology
      • 7.3.5.6.3.Rest of Europe over-the-counter tests market, by distribution channel
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Asia-Pacific over-the-counter tests market, by product type
    • 7.4.3.Asia-Pacific over-the-counter tests market, by technology
    • 7.4.4.Asia-Pacific over-the-counter tests market, by distribution channel
    • 7.4.5.Market size and forecast, by country
      • 7.4.5.1.China
      • 7.4.5.1.1.China over-the-counter tests market, by product type
      • 7.4.5.1.2.China over-the-counter tests market, by technology
      • 7.4.5.1.3.China over-the-counter tests market, by distribution channel
      • 7.4.5.2.Japan
      • 7.4.5.2.1.Japan over-the-counter tests market, by product type
      • 7.4.5.2.2.Japan over-the-counter tests market, by technology
      • 7.4.5.2.3.Japan over-the-counter tests market, by distribution channel
      • 7.4.5.3.India
      • 7.4.5.3.1.India over-the-counter tests market, by product type
      • 7.4.5.3.2.India over-the-counter tests market, by technology
      • 7.4.5.3.3.India over-the-counter tests market, by distribution channel
      • 7.4.5.4.Australia
      • 7.4.5.4.1.Australia over-the-counter tests market, by product type
      • 7.4.5.4.2.Australia over-the-counter tests market, by technology
      • 7.4.5.4.3.Australia over-the-counter tests market, by distribution channel
      • 7.4.5.5.South Korea
      • 7.4.5.5.1.South Korea over-the-counter tests market, by product type
      • 7.4.5.5.2.South Korea over-the-counter tests market, by technology
      • 7.4.5.5.3.South Korea over-the-counter tests market, by distribution channel
      • 7.4.5.6.Rest of Asia-Pacific
      • 7.4.5.6.1.Rest of Asia-Pacific over-the-counter tests market, by product type
      • 7.4.5.6.2.Rest of Asia-Pacific over-the-counter tests market, by technology
      • 7.4.5.6.3.Rest of Asia-Pacific over-the-counter tests market, by distribution channel
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.LAMEA over-the-counter tests market, by product type
    • 7.5.3.LAMEA over-the-counter tests market, by technology
    • 7.5.4.LAMEA over-the-counter tests market, by distribution channel
    • 7.5.5.Market size and forecast, by country
      • 7.5.5.1.Brazil
      • 7.5.5.1.1.Brazil over-the-counter tests market, by product type
      • 7.5.5.1.2.Brazil over-the-counter tests market, by technology
      • 7.5.5.1.3.Brazil over-the-counter tests market, by distribution channel
      • 7.5.5.2.Saudi Arabia
      • 7.5.5.2.1.Saudi Arabia over-the-counter tests market, by product type
      • 7.5.5.2.2.Saudi Arabia over-the-counter tests market, by technology
      • 7.5.5.2.3.Saudi Arabia over-the-counter tests market, by distribution channel
      • 7.5.5.3.South Africa
      • 7.5.5.3.1.South Africa over-the-counter tests market, by product type
      • 7.5.5.3.2.South Africa over-the-counter tests market, by technology
      • 7.5.5.3.3.South Africa over-the-counter tests market, by distribution channel
      • 7.5.5.4.Rest of LAMEA
      • 7.5.5.4.1.Rest of LAMEA over-the-counter tests market, by product type
      • 7.5.5.4.2.Rest of LAMEA over-the-counter tests market, by technology
      • 7.5.5.4.3.Rest of LAMEA over-the-counter tests market, by distribution channel

CHAPTER 8:COMPANY PROFILES

  • 8.1.Abbott Laboratories
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
    • 8.1.6.Key strategic moves and developments
  • 8.2.Abingdon Health PLC
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
    • 8.2.6.Key strategic moves and developments
  • 8.3.AccuBioTech Co., Ltd
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Key strategic moves and developments
  • 8.4.Acon Laboratories, INC.
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Key strategic moves and developments
  • 8.5.B. Braun Melsungen AG
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
  • 8.6.Becton, Dickinson and Company
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
    • 8.6.6.Key strategic moves and developments
  • 8.7.Clip Health
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Key strategic moves and developments
  • 8.8.Dario Health Corp.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
  • 8.9.Ellume Health Ltd.
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Key strategic moves and developments
  • 8.10.Eurofins Scientific Group
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance
    • 8.10.6.Key strategic moves and developments
  • 8.11.F. Hoffmann-La Roche AG (Roche Diagnostics)
    • 8.11.1.Company overview
    • 8.11.2.Company snapshot
    • 8.11.3.Operating business segments
    • 8.11.4.Product portfolio
    • 8.11.5.Business performance
    • 8.11.6.Key strategic moves and developments
  • 8.12.Lia Diagnostics Inc.
    • 8.12.1.Company overview
    • 8.12.2.Company snapshot
    • 8.12.3.Operating business segments
    • 8.12.4.Product portfolio
  • 8.13.LifeScan IP Holdings, LLC
    • 8.13.1.Company overview
    • 8.13.2.Company snapshot
    • 8.13.3.Operating business segments
    • 8.13.4.Product portfolio
    • 8.13.5.Key strategic moves and developments
  • 8.14.Lucira Health, Inc.
    • 8.14.1.Company overview
    • 8.14.2.Company snapshot
    • 8.14.3.Operating business segments
    • 8.14.4.Product portfolio
    • 8.14.5.Business performance
    • 8.14.6.Key strategic moves and developments
  • 8.15.Now Diagnostics Inc.
    • 8.15.1.Company overview
    • 8.15.2.Company snapshot
    • 8.15.3.Operating business segments
    • 8.15.4.Product portfolio
    • 8.15.5.Key strategic moves and developments
  • 8.16.Orasure Technologies Inc.
    • 8.16.1.Company overview
    • 8.16.2.Company snapshot
    • 8.16.3.Operating business segments
    • 8.16.4.Product portfolio
    • 8.16.5.Business performance
    • 8.16.6.Key strategic moves and developments
  • 8.17.PHC Holdings Corporation
    • 8.17.1.Company overview
    • 8.17.2.Company snapshot
    • 8.17.3.Operating business segments
    • 8.17.4.Product portfolio
    • 8.17.5.Key strategic moves and developments
  • 8.18.Quidel Corporation
    • 8.18.1.Company overview
    • 8.18.2.Company snapshot
    • 8.18.3.Operating business segments
    • 8.18.4.Product portfolio
    • 8.18.5.Business performance
    • 8.18.6.Key strategic moves and developments
  • 8.19.SD Biosensor, Inc.
    • 8.19.1.Company overview
    • 8.19.2.Company snapshot
    • 8.19.3.Operating business segments
    • 8.19.4.Product portfolio
    • 8.19.5.Business performance
    • 8.19.6.Key strategic moves and developments
  • 8.20.Sinocare Inc.
    • 8.20.1.Company overview
    • 8.20.2.Company snapshot
    • 8.20.3.Operating business segments
    • 8.20.4.Product portfolio

LIST OF TABLES

  • TABLE 01.GLOBAL OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 02.GLOBAL OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 (UNITS)
  • TABLE 03.OVER-THE-COUNTER TEST MARKET FOR GLUCOSE MONITORING TESTS BY TYPE, 2020-2030 ($MILLION)
  • TABLE 04.OVER-THE-COUNTER TEST MARKET FOR GLUCOSE MONITORING TESTS BY TYPE, 2020-2030 (UNITS)
  • TABLE 05.OVER-THE-COUNTER TESTS MARKET FOR GLUCOSE MONITORING TESTS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.OVER-THE-COUNTER TESTS MARKET FOR GLUCOSE MONITORING TESTS, BY REGION, 2020-2030 (UNITS)
  • TABLE 07.OVER-THE-COUNTER TEST MARKET FOR PREGNANCY & FERTILITY TESTS BY TYPE, 2020-2030 ($MILLION)
  • TABLE 08.OVER-THE-COUNTER TEST MARKET FOR PREGNANCY & FERTILITY TESTS BY TYPE, 2020-2030 (UNITS)
  • TABLE 09.OVER-THE-COUNTER TEST MARKET FOR PREGNANCY AND FERTILITY TESTS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 10.OVER-THE-COUNTER TEST MARKET FOR PREGNANCY AND FERTILITY TESTS, BY REGION, 2020-2030 (UNITS)
  • TABLE 11.OVER-THE-COUNTER TESTS MARKET FOR COAGULATION MONITORING TESTS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 12.OVER-THE-COUNTER TEST MARKET FOR COAGULATION MONITORING TESTS, BY REGION, 2020-2030 (UNITS)
  • TABLE 13.OVER-THE-COUNTER TESTS MARKET FOR URINALYSIS TESTS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 14.OVER-THE-COUNTER TEST MARKET FOR URINALYSIS TESTS, BY REGION, 2020-2030 (UNITS)
  • TABLE 15.OVER-THE-COUNTER TESTS MARKET FOR CHOLESTEROL TESTS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 16.OVER-THE-COUNTER TEST MARKET FOR CHOLESTEROL TESTS, BY REGION, 2020-2030 (UNITS)
  • TABLE 17.OVER-THE-COUNTER TESTS MARKET FOR OTHER TESTS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 18.OVER-THE-COUNTER TEST MARKET FOR OTHERS TEST, BY REGION, 2020-2030 (UNITS)
  • TABLE 19.GLOBAL OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 20.OVER-THE-COUNTER TESTS MARKET FOR LATERAL FLOW ASSAYS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 21.OVER-THE-COUNTER TESTS MARKET FOR IMMUNOASSAYS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 22.OVER-THE-COUNTER TESTS MARKET FOR DIPSTICKS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 23.GLOBAL OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 24.OVER-THE-COUNTER TESTS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 25.OVER-THE-COUNTER TESTS MARKET FOR RETAIL PHARMACIES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 26.OVER-THE-COUNTER TESTS MARKET FOR ONLINE PHARMACIES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 27.OVER-THE-COUNTER TESTS MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 28.NORTH AMERICA OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 29.NORTH AMERICA OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 30.NORTH AMERICA OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 31.NORTH AMERICA OVER-THE-COUNTER TESTS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 32.U.S. OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 33.U.S. OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 34.U.S. OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 35.CANADA OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 36.CANADA OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 37.CANADA OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 38.MEXICO OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 39.MEXICO OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 40.MEXICO OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 41.EUROPE OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 42.EUROPE OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 43.EUROPE OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 44.EUROPE OVER-THE-COUNTER TESTS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 45.GERMANY OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 46.GERMANY OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 47.GERMANY OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 48.FRANCE OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 49.FRANCE OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 50.FRANCE OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 51.UK OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 52.UK OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 53.UK OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 54.ITALY OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 55.ITALY OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 56.ITALY OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 57.SPAIN OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 58.SPAIN OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 59.SPAIN OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 60.REST OF EUROPE OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 61.REST OF EUROPE OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 62.REST OF EUROPE OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 63.ASIA-PACIFIC OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 64.ASIA-PACIFIC OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 65.ASIA-PACIFIC OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 66.ASIA-PACIFIC OVER-THE-COUNTER TESTS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 67.CHINA OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 68.CHINA OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 69.CHINA OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 70.JAPAN OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 71.JAPAN OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 72.JAPAN OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 73.INDIA OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 74.INDIA OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 75.INDIA OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 76.AUSTRALIA OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 77.AUSTRALIA OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 78.AUSTRALIA OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 79.SOUTH KOREA OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 80.SOUTH KOREA OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 81.SOUTH KOREA OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 82.REST OF ASIA-PACIFIC OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 83.REST OF ASIA-PACIFIC OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 84.REST OF ASIA-PACIFIC OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 85.LAMEA OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 86.LAMEA OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 87.LAMEA OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 88.LAMEA OVER-THE-COUNTER TESTS MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 89.BRAZIL OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 90.BRAZIL OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 91.BRAZIL OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 92.SAUDI ARABIA OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 93.SAUDI ARABIA OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 94.SAUDI ARABIA OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 95.SOUTH AFRICA OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 96.SOUTH AFRICA OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 97.SOUTH AFRICA OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 98.REST OF LAMEA OVER-THE-COUNTER TESTS MARKET, BY PRODUCT TYPE, 2020-2030 ($MILLION)
  • TABLE 99.REST OF LAMEA OVER-THE-COUNTER TESTS MARKET, BY TECHNOLOGY, 2020-2030 ($MILLION)
  • TABLE 100.REST OF LAMEA OVER-THE-COUNTER TESTS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 ($MILLION)
  • TABLE 101.ABBOTT: COMPANY SNAPSHOT
  • TABLE 102.ABBOTT: OPERATING SEGMENTS
  • TABLE 103.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 104.ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 105.ABINGDON HEALTH: COMPANY SNAPSHOT
  • TABLE 106.ABINGDON HEALTH: OPERATING SEGMENTS
  • TABLE 107.ABINGDON HEALTH: PRODUCT PORTFOLIO
  • TABLE 108.ABINGDON HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109.ACCUBIOTECH: COMPANY SNAPSHOT
  • TABLE 110.ACCUBIOTECH: OPERATING SEGMENTS
  • TABLE 111.ACCUBIOTECH: PRODUCT PORTFOLIO
  • TABLE 112.ACCUBIOTECH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113.ACON LABORATORIES: COMPANY SNAPSHOT
  • TABLE 114.ACON LABORATORIES: OPERATING SEGMENTS
  • TABLE 115.ACON LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 116.ACON LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117.B. BRAUN: COMPANY SNAPSHOT
  • TABLE 118.B. BRAUN: OERATING SEGMENT
  • TABLE 119.B. BRAUN: PRODUCT PORTFOLIO
  • TABLE 120.BD: COMPANY SNAPSHOT
  • TABLE 121.BD: OPERATING SEGMENTS
  • TABLE 122.BD: PRODUCT PORTFOLIO
  • TABLE 123.BD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 124.CLIP HEALTH: COMPANY SNAPSHOT
  • TABLE 125.CLIP HEALTH: OERATING SEGMENT
  • TABLE 126.CLIP HEALTH: PRODUCT PORTFOLIO
  • TABLE 127.CLIP HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 128.DARIO HEALTH: COMPANY SNAPSHOT
  • TABLE 129.DARIO HEALTH: OERATING SEGMENT
  • TABLE 130.DARIO HEALTH: PRODUCT PORTFOLIO
  • TABLE 131.ELLUME HEALTH: COMPANY SNAPSHOT
  • TABLE 132.ELLUME HEALTH: OERATING SEGMENT
  • TABLE 133.ELLUME HEALTH: PRODUCT PORTFOLIO
  • TABLE 134.ELLUME HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 135.EUROFINS: COMPANY SNAPSHOT
  • TABLE 136.EUROFINS: OPERATING SEGMENTS
  • TABLE 137.EUROFINS: PRODUCT PORTFOLIO
  • TABLE 138.EUROFINS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 139.ROCHE: COMPANY SNAPSHOT
  • TABLE 140.ROCHE: OPERATING SEGMENTS
  • TABLE 141.ROCHE: PRODUCT PORTFOLIO
  • TABLE 142.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 143.LIA DIAGNOSTICS: COMPANY SNAPSHOT
  • TABLE 144.LIA DIAGNOSTICS: OPERATING SEGMENTS
  • TABLE 145.LIA DIAGNOSTICS: PRODUCT PORTFOLIO
  • TABLE 146.LIFESCAN IP: COMPANY SNAPSHOT
  • TABLE 147.LIFESCAN IP: OERATING SEGMENT
  • TABLE 148.LIFESCAN IP: PRODUCT PORTFOLIO
  • TABLE 149.LIFESCAN IP: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 150.LUCIRA HEALTH: COMPANY SNAPSHOT
  • TABLE 151.LUCIRA HEALTH: OPERATING SEGMENTS
  • TABLE 152.LUCIRA HEALTH: PRODUCT PORTFOLIO
  • TABLE 153.LUCIRA HEALTH: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 154.NOW DIAGNOSTICS: COMPANY SNAPSHOT
  • TABLE 155.NOW DIAGNOSTICS: OPERATING SEGMENTS
  • TABLE 156.NOW DIAGNOSTICS: PRODUCT PORTFOLIO
  • TABLE 157.NOW DIAGNOSTICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 158.ORASURE TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 159.ORASURE TECHNOLOGIES: OERATING SEGMENT
  • TABLE 160.ORASURE TECHNOLOGIES: PRODUCT PORTFOLIO
  • TABLE 161.ORASURE TECHNOLOGIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 162.PHC HOLDINGS: COMPANY SNAPSHOT
  • TABLE 163.PHC HOLDINGS: OPERATING SEGMENTS
  • TABLE 164.PHC HOLDINGS: PRODUCT PORTFOLIO
  • TABLE 165.PHC HOLDINGS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 166.QUIDEL: COMPANY SNAPSHOT
  • TABLE 167.QUIDEL: OPERATING SEGMENTS
  • TABLE 168.QUIDEL: PRODUCT PORTFOLIO
  • TABLE 169.QUIDEL: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 170.SD BIOSENSOR: COMPANY SNAPSHOT
  • TABLE 171.SD BIOSENSOR: OPERATING SEGMENTS
  • TABLE 172.SD BIOSENSOR: PRODUCT PORTFOLIO
  • TABLE 173.SD BIOSENSOR: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 174.SINOCARE: COMPANY SNAPSHOT
  • TABLE 175.SINOCARE: OERATING SEGMENT
  • TABLE 176.SINOCARE: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.OVER-THE-COUNTER TESTS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2019-2021
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021
  • FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 08.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 09.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 10.MODERATE INTENSITY OF RIVALRY
  • FIGURE 11.TOP PLAYER POSITIONING, 2020
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.OVER-THE-COUNTER TEST MARKET FOR BLOOD GLUCOSE METERS, 2020-2030 ($MILLION)
  • FIGURE 14.OVER-THE-COUNTER TEST MARKET FOR TESTING STRIPS, 2020-2030 ($MILLION)
  • FIGURE 15.OVER-THE-COUNTER TEST MARKET FOR LANCETS, 2020-2030 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER TESTS MARKET FOR GLUCOSE MONITORING TESTS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 17.OVER-THE-COUNTER TESTS MARKET FOR PREGNANCY TEST, 2020-2030 ($MILLION)
  • FIGURE 18.OVER-THE-COUNTER TESTS MARKET FOR FERTILITY TEST, 2020-2030 ($MILLION)
  • FIGURE 19.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER TESTS MARKET FOR PREGNANCY & FERTILITY TESTS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 20.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER TESTS MARKET FOR COAGULATION MONITORING TESTS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 21.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER TESTS MARKET FOR URINALYSIS TESTS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 22.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER TESTS MARKET FOR CHOLESTEROL TESTS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 23.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER TESTS MARKET FOR OTHER TESTS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 24.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER TESTS MARKET FOR LATERAL FLOW ASSAYS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 25.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER TESTS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 26.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER TESTS MARKET FOR DIPSTICKS, BY COUNTRY, 2020-2030 (%)
  • FIGURE 27.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER TESTS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2020-2030 (%)
  • FIGURE 28.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER TESTS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020-2030 (%)
  • FIGURE 29.COMPARATIVE ANALYSIS OF OVER-THE-COUNTER TESTS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2020-2030 (%)
  • FIGURE 30.ABBOTT: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 31.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 32.ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 33.ABINGDON HEALTH: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 34.ABINGDON HEALTH: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 35.ABINGDON HEALTH: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 36.B. BRAUN: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 37.B. BRAUN: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 38.B. BRAUN: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 39.BD: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 40.BD: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 41.BD: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 42.DARIO HEALTH: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 43.EUROFINS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 44.EUROFINS: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 45.ROCHE: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 46.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 47.ROCHE: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 48.LUCIRA HEALTH: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 49.ORASURE TECHNOLOGIES: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 50.ORASURE TECHNOLOGIES: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 51.ORASURE TECHNOLOGIES: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 52.QUIDEL: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 53.QUIDEL: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 54.SD BIOSENSOR: NET SALES, 2018-2020 ($MILLION)